Mesoblast Ltd - Company Profile
Powered by 
All the data and insights you need on Mesoblast Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Mesoblast Ltd Strategy Report
- Understand Mesoblast Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Mesoblast Ltd (Mesoblast) is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate, remestemcel-L, is in Phase III clinical trials under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, and end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform to discover and treat cardiac diseases, and hematological diseases, mesenchymal lineage adult stem cells (MLCs), spine and musculoskeletal disorders and immune-mediated and inflammatory conditions. The company has operations in the US, Australia, and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.
Headquarters
Australia
Address
L 38 55 Collins St, Melbourne, Victoria, 3000
Website
www.mesoblast.com
Telephone
61 3 96396036
No of Employees
83
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MSB (ASX)
Revenue (2022)
$7.5M
-26.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
10.4%
(2022 vs 2021)
Market Cap*
$550.5M
Net Profit Margin (2022)
XYZ
-22.1%
(2022 vs 2021)
* As of and is in US$
Mesoblast Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Ryoncil |
| Remestemcel-L: | Revascor |
| Steroid-Refractory Acute Graft Versus Host Disease (Children) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In February, the company received approval from the US Food and Drug Administration for its allogeneic cell therapy Revascor (rexlemestrocel-L) from the randomized controlled trial in children with hypoplastic left heart syndrome. |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with the Blood and Marrow Transplant Clinical Trials Network to develop a pivotal trial of Ryoncil (remestemcel-L) in the treatment of adults with steroid-refractory acute graft versus host disease. |
| 2023 | Regulatory Approval | In February, the company secured an approval from the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies for Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration in combination with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc. |
Competitor Comparison
| Key Parameters | Mesoblast Ltd | CSL Ltd | Acrux Ltd | Genetic Technologies Ltd | IDT Australia Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Melbourne | Melbourne | Melbourne | Melbourne | Melbourne |
| State/Province | Victoria | Victoria | Victoria | Victoria | Victoria |
| No. of Employees | 83 | 32,065 | 43 | 60 | 156 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Silviu Itescu | Managing Director; Director; Chief Executive Officer | Executive Board | 2011 | - |
| Eric Rose, MD | Chief Medical Officer; Director | Executive Board | 2022 | - |
| Dagmar Rosa-Bjorkeson | Chief Operating Officer | Senior Management | 2021 | - |
| Andrew Chaponnel | Chief Financial Officer - Interim | Senior Management | 2021 | - |
| Joseph R. Swedish | Chairman | Non Executive Board | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward